Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303650 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Zetian Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou, 510130, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Network Pharmacology, Cell Proliferation, Apoptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Program Research Project of the Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou Chinese Medicine and Integrative Medicine Science and Technology Project, Scientific Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
HuaChanSu (HCS) or Cinobufacini injection is an aqueous extract of the dried skin of Bufo bufo gargarigans , and has anti-tumor effects. The aim of this study was to evaluate the possible therapeutic effect of HCS against breast cancer (BRCA) using cytology, network pharmacology, and molecular biology approaches. The half-inhibitory concentration (IC 50 ) of HCS in the BRCA cells was determined by cytotoxicity assay, and were accordingly treated with high and low doses HCS in the TUNEL and scratch assays. The potential targets of HCS in the BRCA cells were identified through functional enrichment analysis and protein-protein interaction (PPI) networks, and verified by molecular docking. The expression levels of key signaling pathways-related proteins in HCS-treated BRCA cells by western blotting. HCS inhibited the proliferation and migration of MCF-7 and MDA-MB-231 cells, and induced apoptosis in a dose-dependent manner. Furthermore, we screened 289 core HCS targets against BRCA, which were primarily enriched in the PI3K-AKT, MAPK chemokines, and other. signaling pathways. In addition, PIK3CA, PIK3CD, and MTOR were confirmed as HCS targets by molecular docking. Consistent with this, we observed a reduction in the expression levels of phosphorylated PI3K, AKT, and MTOR in the HCS-treated BRCA cells. Taken together, our findings suggest that HCS inhibits the growth of BRCA cells by targeting the PI3K-AKT pathway, and warrants further investigation as a therapeutic agent for treating patients with BRCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou, 510130, China.
- The First School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
ORCID-Profile: Zhenhuai Yang
Förderung
- Youth Program Research Project of the Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University
- Guangzhou Chinese Medicine and Integrative Medicine Science and Technology Project
- Scientific Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine
Zitieren
APA
Yang, Z., Wang, Y., Huang, S., Geng, Y., Yang, Z., & Yang, Z. (2024). Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0303650
Vancouver
Yang Z, Wang Y, Huang S, Geng Y, Yang Z, Yang Z. Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0303650
BibTeX
@article{Yang2024,
author = {Yang, Zetian and Wang, Yifan and Huang, Shuicai and Geng, Yi and Yang, Zejuan and Yang, Zhenhuai},
title = {Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303650}
}
EUVIMED